Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Giannoula, Yvonne"'
Publikováno v:
In Biomedical Journal June 2023 46(3)
Autor:
Ye, Xiaofei *, Maglione, Paul J. *, Wehr, Claudia *, Li, Xiaobo *, *, Wang, Yating, Abolhassani, Hassan, Deripapa, Elena, Liu, Dongbing, Borte, Stephan, Du, Likun, Wan, Hui, Plötner, Andreas, Giannoula, Yvonne, Ko, Huai-Bin, Hou, Yong, Zhu, Shida, Grossman, Jennifer K., Sander, Birgitta, Grimbacher, Bodo, Hammarström, Lennart *, Fedorova, Alina, Rosenzweig, Sergio D., Shcherbina, Anna, Wu, Kui, Warnatz, Klaus, Cunningham-Rundles, Charlotte, Pan-Hammarström, Qiang *
Publikováno v:
In Blood Advances 27 September 2022 6(18):5403-5414
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Hamdan, Firas, Ylösmäki, Erkko, Chiaro, Jacopo, Giannoula, Yvonne, Long, Maeve, Fusciello, Manlio, Feola, Sara, Martins, Beatriz, Feodoroff, Michaela, Antignani, Gabriella, Russo, Salvatore, Kari, Otto, Lee, Moon, Järvinen, Petrus, Nisen, Harry, Kreutzman, Anna, Leusen, Jeanette, Mustjoki, Satu, McWilliams, Thomas G., Grönholm, Mikaela, Cerullo, Vincenzo
Background Despite the success of immune checkpoint inhibitors against PD-L1 in the clinic, only a fraction of patients benefit from such therapy. A theoretical strategy to increase efficacy would be to arm such antibodies with Fc-mediated effector m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::5be391930e9479cba12e771a181d340c
http://hdl.handle.net/11588/879805
http://hdl.handle.net/11588/879805
Autor:
Hamdan, Firas, Martins, Beatriz, Feodoroff, Michaela, Giannoula, Yvonne, Feola, Sara, Fusciello, Manlio, Chiaro, Jacopo, Antignani, Gabriella, Grönholm, Mikaela, Ylösmäki, Erkko, Cerullo, Vincenzo
Publikováno v:
Molecular Therapy. Methods & Clinical Development
Molecular Therapy: Methods & Clinical Development, Vol 20, Iss, Pp 625-634 (2021)
Molecular Therapy: Methods & Clinical Development, Vol 20, Iss, Pp 625-634 (2021)
Oncolytic adenoviruses have become ideal agents in the path toward treating cancer. Such viruses have been engineered to conditionally replicate in malignant cells in which certain signaling pathways have been disrupted. Other than such oncolytic pro
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Hamdan F; Laboratory of Immunovirotherapy, Drug Research Program, University of Helsinki Faculty of Pharmacy, Helsinki, Uusimaa, Finland.; TRIMM, Translational Immunology Research Program, University of Helsinki, Helsinki, Uusimaa, Finland.; Drug Delivery, Drug Research Program, Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland., Ylösmäki E; Laboratory of Immunovirotherapy, Drug Research Program, University of Helsinki Faculty of Pharmacy, Helsinki, Uusimaa, Finland.; TRIMM, Translational Immunology Research Program, University of Helsinki, Helsinki, Uusimaa, Finland.; Drug Delivery, Drug Research Program, Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland., Chiaro J; Laboratory of Immunovirotherapy, Drug Research Program, University of Helsinki Faculty of Pharmacy, Helsinki, Uusimaa, Finland.; TRIMM, Translational Immunology Research Program, University of Helsinki, Helsinki, Uusimaa, Finland.; Drug Delivery, Drug Research Program, Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland., Giannoula Y; Laboratory of Immunovirotherapy, Drug Research Program, University of Helsinki Faculty of Pharmacy, Helsinki, Uusimaa, Finland., Long M; Translational Stem Cell Biology & Metabolism Program, Research Programs Unit, Department of Anatomy, Faculty of Medicine, Biomedicum Helsinki, University of Helsinki, Helsinki, Finland., Fusciello M; Laboratory of Immunovirotherapy, Drug Research Program, University of Helsinki Faculty of Pharmacy, Helsinki, Uusimaa, Finland.; TRIMM, Translational Immunology Research Program, University of Helsinki, Helsinki, Uusimaa, Finland.; Drug Delivery, Drug Research Program, Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland., Feola S; Laboratory of Immunovirotherapy, Drug Research Program, University of Helsinki Faculty of Pharmacy, Helsinki, Uusimaa, Finland.; TRIMM, Translational Immunology Research Program, University of Helsinki, Helsinki, Uusimaa, Finland.; Drug Delivery, Drug Research Program, Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland., Martins B; Laboratory of Immunovirotherapy, Drug Research Program, University of Helsinki Faculty of Pharmacy, Helsinki, Uusimaa, Finland.; TRIMM, Translational Immunology Research Program, University of Helsinki, Helsinki, Uusimaa, Finland.; Drug Delivery, Drug Research Program, Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland., Feodoroff M; Laboratory of Immunovirotherapy, Drug Research Program, University of Helsinki Faculty of Pharmacy, Helsinki, Uusimaa, Finland.; TRIMM, Translational Immunology Research Program, University of Helsinki, Helsinki, Uusimaa, Finland.; Drug Delivery, Drug Research Program, Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland., Antignani G; Laboratory of Immunovirotherapy, Drug Research Program, University of Helsinki Faculty of Pharmacy, Helsinki, Uusimaa, Finland.; TRIMM, Translational Immunology Research Program, University of Helsinki, Helsinki, Uusimaa, Finland.; Drug Delivery, Drug Research Program, Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland., Russo S; Laboratory of Immunovirotherapy, Drug Research Program, University of Helsinki Faculty of Pharmacy, Helsinki, Uusimaa, Finland.; TRIMM, Translational Immunology Research Program, University of Helsinki, Helsinki, Uusimaa, Finland.; Drug Delivery, Drug Research Program, Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland., Kari O; Drug Delivery, Drug Research Program, Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland., Lee M; TRIMM, Translational Immunology Research Program, University of Helsinki, Helsinki, Uusimaa, Finland.; Hematology Research Unit Helsinki, University of Helsinki, Helsinki, Uusimaa, Finland., Järvinen P; Abdominal Center, Urology, Helsinki University Central Hospital, Helsinki, Uusimaa, Finland., Nisen H; Abdominal Center, Urology, Helsinki University Central Hospital, Helsinki, Uusimaa, Finland., Kreutzman A; Laboratory of Immunovirotherapy, Drug Research Program, University of Helsinki Faculty of Pharmacy, Helsinki, Uusimaa, Finland.; TRIMM, Translational Immunology Research Program, University of Helsinki, Helsinki, Uusimaa, Finland.; Drug Delivery, Drug Research Program, Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland., Leusen J; Center for Translational Immunology, UMC Utrecht, Utrecht, Netherlands., Mustjoki S; TRIMM, Translational Immunology Research Program, University of Helsinki, Helsinki, Uusimaa, Finland.; Hematology Research Unit Helsinki, University of Helsinki, Helsinki, Uusimaa, Finland.; iCAN Digital Precision Cancer Medicine Flagship, University of Helsinki, Helsinki, Finland.; Department of Clinical Chemistry and Hematology, University of Helsinki, Helsinki, Finland., McWilliams TG; Translational Stem Cell Biology & Metabolism Program, Research Programs Unit, Department of Anatomy, Faculty of Medicine, Biomedicum Helsinki, University of Helsinki, Helsinki, Finland.; Department of Anatomy, University of Helsinki, Helsinki, Finland., Grönholm M; Laboratory of Immunovirotherapy, Drug Research Program, University of Helsinki Faculty of Pharmacy, Helsinki, Uusimaa, Finland.; TRIMM, Translational Immunology Research Program, University of Helsinki, Helsinki, Uusimaa, Finland.; Drug Delivery, Drug Research Program, Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland.; iCAN Digital Precision Cancer Medicine Flagship, University of Helsinki, Helsinki, Finland., Cerullo V; Laboratory of Immunovirotherapy, Drug Research Program, University of Helsinki Faculty of Pharmacy, Helsinki, Uusimaa, Finland vincenzo.cerullo@helsinki.fi.; TRIMM, Translational Immunology Research Program, University of Helsinki, Helsinki, Uusimaa, Finland.; Drug Delivery, Drug Research Program, Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland.; iCAN Digital Precision Cancer Medicine Flagship, University of Helsinki, Helsinki, Finland.; Department of Molecular Medicine and Medical Biotechnology and CEINGE, Naples University 24 Federico II, 80131, Naples, Italy.
Publikováno v:
Journal for immunotherapy of cancer [J Immunother Cancer] 2021 Aug; Vol. 9 (8).